

**SPONDYLOARTHRITIS & FRIENDS IN SARDINIA** 3<sup>rd</sup> edition


# GRAPPA WORKSHOP 2024

12-13-14 September 2024, Cagliari

Aula Magna Rectorate Palazzo Belgrano University of Cagliari  
and Hotel Regina Margherita

Honorary Presidents:  
**Prof. Oliver Fitzgerald**  
**Prof. Philip Helliwell**

Presidents  
Scientific coordinators  
**Prof. Alberto Cauli**  
**Prof. Paolo Gisondi**



# GRAPPA

GROUP FOR RESEARCH  
AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS



**UNICA**

UNIVERSITÀ  
DEGLI STUDI  
DI CAGLIARI



**AZIENDA  
OSPEDALIERO  
UNIVERSITARIA  
DI CAGLIARI**

**GRAPPA**

GROUP FOR RESEARCH  
AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS

## RAZIONALE SCIENTIFICO

La malattia Psoriasica è una condizione eterogenea che interessa la cute, l'apparato muscoloscheletrico e frequentemente l'intestino e l'occhio. Inoltre, molto spesso, il quadro clinico si caratterizza per le comorbidità metaboliche. Questo scenario complesso si riflette nella necessità di una gestione congiunta tra diversi specialisti, e la necessità di una valutazione clinica di tutti i possibili domini di malattia. Il Gruppo per la Ricerca e la Valutazione della Psoriasi e Artrite Psoriasica (GRAPPA), supporta i reumatologi, dermatologi e altri clinici nella gestione condivisa di questi pazienti nella pratica clinica quotidiana. Durante il congresso, esperti nazionali e internazionali discuteranno di patogenesi e terapia della malattia psoriasica focalizzando sulle nuove strategie e trattamenti. Tra i temi principali che verranno evidenziati figurano l'immunopatogenesi della flogosi cutanea, muscoloscheletrica, intestinale e a carico dell'occhio, inoltre le possibili modalità di intervento in questi pathways. L'approccio multidisciplinare e la necessità di nuove strategie verranno discusse in dettaglio.

## RATIONALE

Psoriatic disease is a heterogeneous skin and musculoskeletal condition which frequently affect the gut and the eye. Furthermore, metabolic comorbidities quite often also characterized the clinical picture. This complex scenario is reflected by the need of a comprehensive collaborative management across specialities, and the clinical evaluation must be carried out considering the various clinical domains.

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) supports rheumatologists, dermatologists and other clinicians to share the experience in the management of these patients in clinical practice. During the meeting national and international experts in this field will discuss about pathogenetic and therapeutic aspects of psoriatic disease focusing on new strategies and treatments. Key messages to be delivered in the workshop include the immunopathogenesis of skin, musculoskeletal, gut and eye inflammation, as well as the possible way to interfere with these pathways. The multidisciplinary approach and the need of new strategies will be discussed in deep.



ore 14.00 *Registration nearby Rettorato Aula Magna of the University of Cagliari*

**SCANNING THE SPECTRUM OF PSORIATIC DISEASE: PSO, PSA, IBD AND AAU ASSOCIATIONS: COINCIDENCE, FRIENDSHIP OR MARRIAGE?**

ore 14.30 *Welcome from the University and AOU Cagliari*

ore 14.40 Meeting presentation and objectives  
**Prof. Alberto Cauli - Prof. Paolo Gisondi - Prof.ssa Laura Atzori**

ore 14.50 GRAPPA and its contribution to Psoriatic Disease  
**Prof. Oliver Martin Fitzgerald GRAPPA President**

**INTRODUCTIVE LECTURES**

Chairs: **Prof.ssa Maria Antonietta D'Agostino, Roma**  
**Prof.ssa Laura Atzori, Cagliari**

ore 15.10 The comorbid psoriatic patient: from metabolic to pain disturbances. How they influence quality of life and disease perception in PSO/PsA patients  
**Prof. Kurt De Vlam, Leuven Flanders (Belgium)**

**PSORIASIS & PSORIATIC ARTHRITIS, "HOW DEEP IS THEIR LOVE"?**

ore 15.30 The Dermatologist point of view  
**Prof. Paolo Gisondi, Verona**

ore 15.50 The Rheumatologist point of view  
**Prof. Alberto Cauli, Cagliari**

ore 16.10 *Discussion*



I SESSION **PSO, PSA & FRIENDS: IBD AND AAU ON THE STAGE**

Chair: **Prof. Francesco Ciccia**, *Napoli*

ore 16.20 General introduction to the topic

**Prof. Francesco Ciccia**, *Napoli*

ore 16.30 Inflammatory bowel diseases (IBD) and the spectrum of Spondyloarthritis

**Prof. Massimo Claudio Fantini**, *Cagliari*

**Prof. Flavio Andrea Caprioli**, *Milano*

ore 17.00 Acute Anterior Uveitis (AAU) and the spectrum of Spondyloarthritis

**Prof. Giuseppe Giannaccare**, *Cagliari*

**Prof.ssa Elisabetta Miserocchi**, *Milano*

ore 17.30 Discussion

ore 17.40 Pausa Coffee Break

II SESSION **FROM PSO TOWARD PSA: THE TRANSITION PROCESS AND THE INTRIGUING OPPORTUNITY OF ITS INTERCEPTION**

Chairs: **Prof. Antonio Costanzo**, *Milano*

**Dott. Antonio Marchesoni**, *Milano*

ore 17.50 The biologic mechanisms underlying the transition from PSO to PSA

**Prof. Carlo Francesco Selmi**, *Milano*

ore 18.10 Which patients with PsO are at risk of PsA ?

**Prof.ssa Francesca Prignano**, *Firenze*

ore 18.30 Discussion among speakers and audience

Chairs: **Prof. Alberto Cauli**, *Cagliari* - **Prof. Paolo Gisondi**, *Verona*

ore 18.40 LECTIO MAGISTRALIS

“The concept of Psoriatic Arthritis, past, present and future”

**Prof. Philip Helliwell**, *Leeds UK*

ore 19.10 End of the day and summary

ore 08.00 *Registration*

ore 08.30 Recap of day one and presentation of day two  
**Prof. Alberto Cauli, Cagliari** - **Prof. Paolo Gisondi, Verona**

III SESSION **WHAT HAVE WE LEARNED FROM ANTI CYTOKINES (TNF-ALPHA, IL-23, IL-17), JAK INHIBITORS AND TARGETED THERAPY IN PSO, PSA, IBD AND AAU**

Chairs: **Prof. Raffaele Scarpa, Napoli**  
**Prof.ssa Maria Concetta Fargnoli, L'Aquila**

ore 08.45 The role of anti - TNF alpha in Psoriatic disease and what have we learned from TNF therapy?  
**Prof. Salvatore D'Angelo, Potenza**  
**Prof.ssa Maria Concetta Fargnoli, L'Aquila**

ore 09.15 The role of IL-17 in Psoriatic disease and what have we learned from anti-IL-17 therapy?  
**Prof.ssa Roberta Ramonda, Padova**  
**Dott.ssa Cristina Mugheddu, Cagliari**

ore 09.45 The role of IL-23 in Psoriatic disease and what have we learned from anti IL-23 therapy?  
**Prof.ssa Maria Sole Chimenti, Roma**  
**Prof. Stefano Piaserico, Padova**

ore 10.15 *Pausa Coffee break*

ore 10.30 What have we learned from anti-JAK therapy in Psoriatic disease?  
**Prof. Michele Maria Luchetti Gentiloni, Ancona**  
**Prof. Giuseppe Lopalco, Bari**

ore 11.00 What have we learned from TYK2 inhibitors in Psoriatic disease?  
**Prof. Antonio Costanzo, Milano**  
**Prof. Paolo Gisondi, Verona**

- ore 11.20 What have we learned from Apremilast therapy in Psoriatic disease?  
**Prof.ssa Rossana Scrivo, Roma**  
**Prof. Angelo Valerio Marzano, Milano**
- ore 11.50 *Discussion among speakers and audience*
- ore 12.00 *Pausa Light Lunch*

IV SESSION **GRAPPA YOUNG SESSION/WORKSHOP:  
DO WE NEED NEW ASSESSMENT TOOLS?**

Chairs: **Prof. Ennio Lubrano, Campobasso**  
**Prof. Matteo Piga, Cagliari**

- ore 13.20 How to score the skin and nails, ups and downs  
**Prof.ssa Maria Esposito, L'Aquila**
- ore 13.40 How to score peripheral joints, spine and entheses (MSK), ups and downs  
**Dott.ssa Ilenia Pantano, Napoli**  
**Dott.ssa Nicoletta Luciano, Milano**  
**Dott. Fabio Massimo Perrotta, Campobasso**
- ore 14.10 How to score PSO/PSA globally (including composite), ups and downs  
**Dott. Francesco Bellinato, Verona**  
**Dott. Fabio Massimo Perrotta, Campobasso**
- ore 14.40 The patient point of view: patient global assessment and its perception of disease  
**Dott.ssa Elisabetta Chessa, Cagliari**  
**Dott.ssa Alessia Frau, Cagliari**



ore 15.10 Is US-doppler scan the new stethoscope for the young rheumatologists?

**Dott. Niccolò Possemato**, *Reggio Emilia*

**Dott. Alen Zabotti**, *Udine*

**Dott. Andrea Delle Sedie**, *Pisa*

ore 15.40 PSO/PsA disease biomarkers

**Dott.ssa Maria Maddalena Angioni**, *Cagliari*

**Dott.ssa Maria Manara**, *Milano*

**Dott. Guido Mioso**, *Padova*

**NO ECM - SPONSORED READING**

Chairs: **Prof. Alberto Cauli**, *Cagliari* - **Prof. Paolo Gisondi**, *Verona*

ore 16.10 Sponsored Reading by NOVARTIS

Bio-experience in PsA Patients: Is Secukinumab the First Choice?

**Dott. Niccolò Possemato**, *Reggio Emilia*

ore 16.30 Sponsored Reading by LILLY

Ixekizumab: pso-psa transition

**Prof. Alessandro Giunta**, *Roma*

ore 16.50 *End of the day and summary*







ore 08.20 *Registration*

ore 08.30 Recap of day two and presentation of day three

**Prof. Alberto Cauli, Cagliari - Prof. Paolo Gisondi, Verona**

V SESSION **ADEQUATE STRATEGIES ARE REQUIRED BEYOND EFFECTIVE DRUGS FOR AN EFFECTIVE MANAGEMENT OF PSORIATIC DISEASE**

Chairs: **Prof. Costantino Pitzalis, London**

**Prof. Christopher Griffiths, Manchester (UK)**

ore 08.40 How to treat PsO: the optimal use of conventional systemics

**Prof. Peter van de Kerkhof, Nijmegen (Netherlands)**

*Discussion*

ore 09.10 How to treat PsO: the optimal use of biologics

**Christopher Griffiths, Manchester (UK)**

*Discussion*

ore 09.40 How to treat PsA: from GRAPPA treatment recommendations, what's next?

**Prof.ssa Laura Coates, Oxford (UK)**

*Discussion*

ore 10.10 The concept of Difficult to Treat (D2T) in PsA

**Prof.ssa Helena Marzo-Ortega, Leeds (UK)**

*Discussion*

ore 10.40 *Pausa Coffee break*



VI SESSION HOT TOPICS AND COLLABORATIVE RESEARCH PROJECTS

Chairs: **Prof. Carlo Salvarani**, *Reggio Emilia*  
**Prof.ssa Caterina Ferreli**, *Cagliari*

ore 11.10 Preventing arthritis development in PsO patients:  
an ambition still so far away to be achieved?

**Dott. Alberto Floris**, *Cagliari*

**Dott. Francesco Bellinato**, *Verona*

*Discussion*

ore 11.40 Treat-to-target: can it really be allied in PsA patients?

**Dott. Antonio Marchesoni**, *Milano*

**Prof.ssa Laura Atzori**, *Cagliari*

*Discussion*

ore 12.10 The SAGE-PsA study: rationale for investigating sex  
and gender influence in PsA

**Prof. Ennio Lubrano**, *Campobasso*

*Discussion*

ore 12.40 *Conclusions – take home messages*

**Prof. Alberto Cauli**, *Cagliari* - **Prof. Paolo Gisondi**, *Verona*

ore 12.50 *Closing of the meeting and ECM forms*

ore 13.00 *Light Lunch*



# FACULTY

**Dott.ssa M. Maddalena Angioni**, *Cagliari*

**Prof.ssa Laura Atzori**, *Cagliari*

**Dott. Francesco Bellinato**, *Verona*

**Prof. Flavio Andrea Caprioli**, *Milano*

**Prof. Alberto Cauli**, *Cagliari*

**Dott.ssa Elisabetta Chessa**, *Cagliari*

**Prof.ssa Maria Sole Chimenti**, *Roma*

**Prof. Francesco Ciccìa**, *Napoli*

**Prof.ssa Laura Coates**, *Oxford*

**Prof. Antonio Costanzo**, *Milano*

**Prof.ssa M. Antonietta D'Agostino**, *Roma*

**Prof. Salvatore D'Angelo**, *Potenza*

**Dott. Andrea Delle Sedie**, *Pisa*

**Prof. Kurt De Vlam**, *Leuven Flanders*

**Prof.ssa Maria Esposito**, *L'Aquila*

**Prof. Massimo Claudio Fantini**, *Cagliari*

**Prof.ssa Maria Concetta Fagnoli**, *L'Aquila*

**Prof.ssa Caterina Ferreli**, *Cagliari*

**Prof. Oliver Martin Fitzgerald**, *Dublin*

**Dott. Alberto Floris**, *Cagliari*

**Dott.ssa Alessia Frau**, *Cagliari*

**Prof. Giuseppe Giannaccare**, *Cagliari*

**Prof. Paolo Gisoni**, *Verona*

**Prof. Alessandro Giunta**, *Roma*

**Prof. Christopher Griffiths**, *Manchester*

**Prof. Philips Helliwell**, *Leeds*



# FACULTY

**Prof. Giuseppe Lopalco**, *Bari*  
**Prof. Michele Maria Luchetti Gentiloni**, *Ancona*  
**Prof. Ennio Lubrano**, *Campobasso*  
**Dott.ssa Nicoletta Luciano**, *Milano*  
**Dott.ssa Maria Manara**, *Milano*  
**Dott. Antonio Marchesoni**, *Milano*  
**Prof. Angelo Valerio Marzano**, *Milano*  
**Prof.ssa Helena Marzo-Ortega**, *Leeds*  
**Dott. Guido Mioso**, *Padova*  
**Prof.ssa Elisabetta Misericchi**, *Milano*  
**Dott.ssa Cristina Mugheddu**, *Cagliari*  
**Dott.ssa Ilenia Pantano**, *Napoli*  
**Dott. Fabio M. Perrotta**, *Campobasso*  
**Prof. Stefano Piaserico**, *Padova*  
**Prof. Matteo Piga**, *Cagliari*  
**Prof. Costantino Pitzalis**, *London*  
**Dott. Niccolò Possemato**, *Reggio Emilia*  
**Prof.ssa Francesca Prignano**, *Firenze*  
**Prof.ssa Roberta Ramonda**, *Padova*  
**Prof. Carlo Salvarani**, *Reggio Emilia*  
**Prof. Raffaele Scarpa**, *Napoli*  
**Prof.ssa Rossana Scrivo**, *Roma*  
**Prof. Carlo Francesco Selmi**, *Milano*  
**Prof. Peter van de Kerkhof**, *Nijmegen*  
**Dott. Alen Zabotti**, *Udine*



Honorary Presidents:

**Prof. Oliver Martin Fitzgerald** GRAPPA President

**Prof. Philip Helliwell** GRAPPA Past-President

Presidents and Scientific coordinators

**Prof. Alberto Cauli - Prof. Paolo Gisondi**

ACCREDITAMENTO ECM

crediti assegnati per Medico Chirurgo specialisti in Reumatologia e Dermatologia.

Saranno invitati anche gli specializzandi in Reumatologia e Dermatologia

**amos**  
Provider Nazionale Standard ECM  
Ass. Interdisciplinare  
Medici Ospedalieri Sardi



Provider Nazionale  
Standard AIMOS

SEGRETERIA ORGANIZZATIVA

**a**  
**aservice**  
studio srl  
Comunicazione e Immagine

Aservice Studio srl

Via Machiavelli 136, 09131 Cagliari

tel 070/ 42939 [posta@aservicestudio.eu](mailto:posta@aservicestudio.eu)

[www.aservicestudio.eu](http://www.aservicestudio.eu)

SEDE DEL CORSO

DAY **1** Aula Magna del Rettorato Palazzo Belgrano  
Università di Cagliari - Via Università 40, Cagliari

DAY **2-3** Hotel Regina Margherita, Cagliari  
Viale Regina Margherita, 44, 09124 Cagliari  
070/ 670342 [booking@hotelreginamargherita.com](mailto:booking@hotelreginamargherita.com)

MODALITA ISCRIZIONE

Iscrizione a numero chiuso con obbligo di pre-iscrizione.

Compilare la scheda di adesione e trasmetterla alla Segreteria Organizzativa:

Aservice Studio srl via Machiavelli 136, 09131 Cagliari tel 070/42939

[posta@aservicestudio.eu](mailto:posta@aservicestudio.eu) - [www.aservicestudio.eu](http://www.aservicestudio.eu)



con il supporto non condizionante di

PLATINUM  
sponsor

The Lilly logo is written in a red, cursive script font.The Novartis logo features a stylized orange and blue flame-like symbol to the left of the word "NOVARTIS" in a blue, sans-serif, all-caps font.

GOLD  
sponsor

The Amgen logo consists of the word "AMGEN" in a bold, blue, sans-serif, all-caps font.The Bristol Myers Squibb logo features a purple stylized flame-like symbol to the left of the text "Bristol Myers Squibb" in a blue, sans-serif font, with a registered trademark symbol.

SILVER  
sponsor

The Abbvie logo is the word "abbvie" in a lowercase, blue, sans-serif font.The UCB logo features a blue square with a white circle containing the letters "ucb" in lowercase. To the right, the text "Inspired by patients. Driven by science." is written in a blue, sans-serif font.

BRONZE  
sponsor

The Alfasigma logo features the word "ALFASIGMA" in a blue, sans-serif, all-caps font, followed by a stylized logo element consisting of a black triangle and a yellow triangle.The Johnson & Johnson logo is the text "Johnson & Johnson" in a bold, red, sans-serif font.The Pfizer logo features a stylized blue and white logo element to the left of the word "Pfizer" in a blue, sans-serif font.The "a service" logo features a small lowercase "a" above the word "service" in a lowercase, sans-serif font.